OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide...
2 insider purchases on record · latest filing 2025-05-19.
Insiders have also filed 18 sale transactions at OKUR.